Lv1
50 积分 2025-03-18 加入
CAR T therapy beyond cancer: the evolution of a living drug
1天前
已完结
Leukapheresis for CAR-T cell production and therapy
1个月前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
1个月前
已完结
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma
2个月前
已完结
New treatment strategies for primary central nervous system lymphoma
2个月前
已完结
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
3个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
3个月前
已完结
CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations
3个月前
已完结
Optimizing the manufacturing and antitumour response of CAR T therapy
4个月前
已完结
Predictors of response to CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a consolidated review
4个月前
已完结
皖公网安备34019202002308
